EugeneShenderovMDD.Phil., F.A.C.P.(He/Him)

PubMed

• Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
  Hannah E Bergom, Laura A Sena, Abderrahman Day, Benjamin Miller, Carly D Miller, John R Lozada, Nicholas Zorko, Jinhua Wang, Eugene Shenderov, Francisco Pereira Lobo, ...> ;NPJ Genomic Medicine. 2024 Jan 22
• 1 citations
  Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
  Singla, N., Nirschl, T., Obradovic, A., Shenderov, E., Lombardo, K., Liu, X., Pons, A., Zarif, J., Rowe, S., Trock, B., Hammers, H., Bivalacqua, T., Pierorazio, P., De...> ;Scientific Reports. 2024 Jan 17
• 1 citations
  MLH1 Loss in Primary Prostate Cancer.
  Sanaz Nourmohammadi Abadchi, Laura A Sena, Emmanuel S Antonarakis, Colin C Pritchard, James R Eshleman, Eric Q Konnick, Stephen J Salipante, Eugene Shenderov, Tamara L...> ;JCO Precision Oncology. 2023 May 1
• 16 citations
  Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
  Eugene Shenderov, Angelo M De Marzo, Tamara L Lotan, Hao Wang, Sin Chan, Su Jin Lim, Hongkai Ji, Mohamad E Allaf, Carolyn Chapman, Paul A Moore, Francine Chen, Kristin...> ;Nature Medicine. 2023 Apr 1
• 3 citations
  B7-H3 and Prostate Cancer: New Therapeutic Dance Partners.
  Eugene Shenderov, Emmanuel S Antonarakis> ;European Urology. 2023 Mar 1
• 8 citations
  Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 157-165 tumor-specific peptide.
  Eugene Shenderov, Matheswaran Kandasamy, Uzi Gileadi, Ji-Li Chen, Dawn Shepherd, James S. Gibbs, Gennaro Prota, Jonathan D. Silk, Jonathan W. Yewdell, Vincenzo Cerundolo> ;Journal for Immunotherapy of Cancer. 2021 Jun 1
• 14 citations
  Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features.
  John-William Sidhom, Ingharan J. Siddarthan, Bo-Shiun Lai, Adam Luo, Bryan C. Hambley, Jennifer Bynum, Amy S. Duffield, Michael B. Streiff, Alison R. Moliterno, Philip...> ;NPJ Precision Oncology. 2021 May 14
• 31 citations
  Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial
  Eugene Shenderov, Karim Boudadi, Wei Fu, Hao Wang, Rana Sullivan, Alice Jordan, Donna Dowling, Rana Harb, Joseph D. Schonhoft, Adam Jendrisak, Michael A. Carducci, Mar...> ;The Prostate. 2021 Feb 26
• 4 citations
  Reimagining Vaccines for Prostate Cancer: Back to the Future.
  Eugene Shenderov, Emmanuel S. Antonarakis> ;Clinical Cancer Research. 2020 Oct 1
• 20 citations
  Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
  Mark C. Markowski, Eugene Shenderov, Mario A. Eisenberger, Sushant Kachhap, Drew M. Pardoll, Samuel R. Denmeade, Emmanuel S. Antonarakis> ;The Prostate. 2020 Apr 1
• 18 citations
  Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
  Eugene Shenderov, Pedro Isaacsson Velho, Anas H. Awan, Hao Wang, Nooshin Mirkheshti, Tamara L. Lotan, Michael A. Carducci, Drew M. Pardoll, Mario A. Eisenberger, Emman...> ;The Prostate. 2019 Aug 7
• 8 citations
  Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
  Bryan C. Hambley, Kelly J. Norsworthy, Jagar Jasem, Jacquelyn W. Zimmerman, Eugene Shenderov, Jonathan Webster, Margaret M. Showel, Lukasz P. Gondek, William Brian Dal...> ;Leukemia Research. 2019 Jun 21
• 125 citations
  Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations
  Emmanuel S. Antonarakis, Farah Shaukat, Pedro Isaacsson Velho, Harsimar B. Kaur, Eugene Shenderov, Drew M. Pardoll, Tamara L. Lotan> ;European Urology. 2019 Mar 1
• 6 citations
  Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Design...
  Eugene Shenderov, Michael A. Gorin, Seohyun Kim, Pamela T. Johnson, Mohamad E. Allaf, Alan W. Partin, Martin G. Pomper, Emmanuel S. Antonarakis, Kenneth J. Pienta, Ste...> ;Urology Case Reports. 2018 Mar 1
• Resistance Is Futile: Engineering the Adoptive T-Cell Therapies of the Future.
  Eugene Shenderov, Richard F. Ambinder> ;Journal of Clinical Oncology. 2018 Jan 24
• 9 citations
  T lymphocytes need less than 3 min to discriminate between peptide MHCs with similar TCR-binding parameters
  Alexandre Brodovitch, Eugene Shenderov, Vincenzo Cerundolo, Pierre Bongrand, Anne Pierres, Philip Anton van der Merwe> ;European Journal of Immunology. 2015 Jun 1
• 108 citations
  NAADP activates two-pore channels on T cell cytolytic granules to stimulate exocytosis and killing.
  Lianne C. Davis, Anthony J. Morgan, Ji Li Chen, Charlotte M. Snead, Duncan Bloor-Young, Eugene Shenderov, Megan N. Stanton-Humphreys, Stuart J. Conway, Grant C. Church...> ;Current Biology. 2012 Dec 18
• 174 citations
  Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time
  Milos Aleksic, Omer Dushek, Hao Zhang, Eugene Shenderov, Ji Li Chen, Vincenzo Cerundolo, Daniel Coombs, P. Anton van der Merwe> ;Immunity. 2010 Feb 26
• 65 citations
  Quantitating T cell cross-reactivity for unrelated peptide antigens.
  Jeffrey Ishizuka, Kristie M. Grebe, Eugene Shenderov, Bjoern Peters, Qiongyu Chen, Yan Chun Peng, Lili Wang, Tao Dong, Valerie Pasquetto, Carla Oseroff, John Sidney, H...> ;Journal of Immunology. 2009 Oct 1
• 84 citations
  Rational development of high-affinity T-cell receptor-like antibodies
  Guillaume Stewart-Jones, Andreas Wadle, A A Hombach, Eugene Shenderov, Gerhard Held, Eliane Fischer, Sascha Kleber, Natko Nuber, Frank Stenner-Liewen, Stefan Bauer, An...> ;Proceedings of the National Academy of Sciences of the United States of America. 2009 Apr 7
• Join now to see all

Lectures

• Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018